FBLN5 and neoplasm: In detail, clinical features (LDH, tumor size, and PLT), mutation features (VHL and KMT2C), mutational signatures (AA signature), copy number alteration features (7q, 3p), transcriptome features (MIR3939, ALDH1A3, LPAR1, FBLN5, and C7), and proteome features (same as the proteome-based model) were selected for the multi-omics classifier construction.